The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

Abstract Background Anti-angiogenic, VEGF inhibitors (VEGFi) increase progression-free survival (PFS) and, in some cases, overall survival in many solid tumours. However, their use has been compromised by a lack of informative biomarkers. We have shown that plasma Tie2 is the first tumour vascular r...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Margherita Carucci, Andrew Clamp, Cong Zhou, Chris Hurt, Rosalind Glasspool, Phillip J. Monaghan, Sally Thirkettle, Michael Wheatley, Madia Mahmood, Monica Narasimham, Tracy Cox, Hilary Morrison, Susan Campbell, Annmarie Nelson, Daniella Holland-Hart, Noreen Hopewell-Kelly, Abin Thomas, Catharine Porter, Magdalena Slusarczyk, Alys Irving, Caroline Dive, Richard Adams, Gordon C. Jayson
Format: Artykuł
Język:English
Wydane: BMC 2024-10-01
Seria:BMC Cancer
Hasła przedmiotowe:
Clinical trial
Ovarian cancer
VEGFi
Tie2
Clinical decision making
Dostęp online:https://doi.org/10.1186/s12885-024-13073-0

Internet

https://doi.org/10.1186/s12885-024-13073-0

Podobne zapisy